obesity research comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Cremasco, V., Woodruff, M. C., Onder, L., Cupovic, J., Nieves-Bonilla, J. M., Schildberg, F. A., Chang, J., Harvey, C. J., Wucherpfennig, B., Ludewig, B., Carroll, M. C., & Turley, S. J. (2014). B cell homeostasis and follicle confines are governed by fibroblastic reticular cells. Nature Immunology, 15(8), 973–981. https://doi.org/10.1038/ni.2965 Li, L., Lu, Y., Zhou, L., Shi, S., Zhu, X., & Zhang, L. (2021). Lymph node fibroblastic reticular cells steer immune responses. Trends in Immunology. https://doi.org/10.1016/j.it.2021.06.002 Link, A., Vogt, T. K., Favre, S., Britschgi, M. R., Acha-Orbea, H., Hinz, B., Cyster, J. G., & Luther, S. A. (2007). Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naïve T cells. Nature Immunology, 8(11), 1255–1265. https://doi.org/10.1038/ni1513 Lütge, M., Pikor, N. B., & Ludewig, B. (2021). Differentiation and activation of fibroblastic reticular cells. Immunological Reviews, 302(1), 32–46. https://doi.org/10.1111/imr.12981 Mueller, S. N., & Germain, R. N. (2015). Stromal cell contributions to the homeostasis and functionality of the immune system. Nature Reviews Immunology, 15(12), 729–740. https://doi.org/10.1038/nri3846 Onder, L., Papadopoulou, C., Lütge, A., Cheng, H.-W., Lütge, M., Perez-Shibayama, C., Gil-Cruz, C., De Martin, A., Kurz, L., Cadosch, N., Pikor, N. B., Rodriguez, R., Born, D., Jochum, W., Leskow, P., Dutly, A., Robinson, M. D., & Ludewig, B. (2025). Fibroblastic reticular cells generate protective intratumoral T cell environments in lung cancer. Cell, 188(2), 430–446.
=== Obsessive–compulsive disorder === In Canada, SSRIs are a first-line treatment of adult obsessive–compulsive disorder (OCD). In the UK, they are first-line treatment only with moderate to severe functional impairment and as second-line treatment for those with mild impairment, though, as of early 2019, this recommendation is being reviewed. SSRIs are more effective than placebo for reducing OCD symptoms and global severity in children and adolescents, and combining them with exposure therapy is probably more effective than using an SSRI alone.
Biden proposed the Build Back Better Act, part of which was incorporated into the Inflation Reduction Act passed in 2022. He appointed Ketanji Brown Jackson to the Supreme Court of the United States. In his foreign policy, the U.S. reentered the Paris Agreement and enacted the New Atlantic Charter. Biden withdrew U.S. troops from Afghanistan in a chaotic exit, after which the Taliban swiftly retook control. He responded to the Russian invasion of Ukraine by imposing sanctions on Russia and authorizing Ukrainian aid. In 2022, Biden supported Finland's and Sweden's bids to join NATO and formally approved their membership. During the Gaza war, he condemned the actions of Hamas, gave Israel strong military and diplomatic support, sent humanitarian aid to the Gaza Strip, and backed a temporary ceasefire proposal before his presidency ended. Concerns about Biden's age and health persisted throughout his presidency. He is the first president to turn 80 years old while in office. Biden initially ran for reelection in 2024, winning the Democratic primaries and becoming the party's presumptive nominee. After his performance in the first presidential debate, intensifying scrutiny from both political parties about his age and health led him to withdraw his candidacy. Biden entered office with majority support, but his approval ratings declined significantly during his presidency, particularly over concerns about inflation and immigration. He is the oldest living former U.S. president since the second inauguration of Donald Trump in 2025, the oldest living former U.S.
Researchers surveyed 1,520 children, ages 9–10, with a four-year follow up and discovered a positive correlation between obesity and low self-esteem in the four-year follow up. They also discovered that decreased self-esteem led to 19% of obese children feeling sad, 48% of them feeling bored, and 21% of them feeling nervous. In comparison, 8% of normal weight children felt sad, 42% of them felt bored, and 12% of them felt nervous. Stress can influence a child's eating habits. Researchers tested the stress inventory of 28 college females and discovered that those who were binge eating had a mean of 29.65 points on the perceived stress scale, compared to the control group who had a mean of 15.19 points. This evidence may demonstrate a link between eating and stress. Feelings of depression can cause a child to overeat. Researchers provided an in-home interview to 9,374 adolescents, in grades seven through 12 and discovered that there was not a direct correlation with children eating in response to depression. Of all the obese adolescents, 8.2% had said to be depressed, compared to 8.9% of the non-obese adolescents who said they were depressed. Antidepressants, however, seem to have very little influence on childhood obesity.
Biochemically, individuals with ALD show very high levels of unbranched, saturated, very long chain fatty acids, particularly cerotic acid (26:0). The level of cerotic acid in plasma does not correlate with clinical presentation. Treatment options for ALD are limited. For the childhood cerebral form, stem cell transplant and gene therapy are options if the disease is detected early in the clinical course. Adrenal insufficiency in ALD patients can be successfully treated. ALD is the most common peroxisomal inborn error of metabolism, with a minimum estimated incidence of 1:42,000 for hemizygotes and 1:16,800 for hemizygotes and heterozygotes, though the incidence is likely to increase with improved newborn screening. It does not have a significantly higher incidence in any specific ethnic group.
Sources: en.wikipedia.org
=== Stoichiometry === Different stoichiometric ratios of reagents can result in different ratios of products formed. On the industrial scale, adding a large amount of reagent A to reagent B may take time. During this, the reagent A that is added is exposed to a much higher stoichiometric amount of reagent B until it is all added, and this imbalance can lead to reagent A prematurely reacting, and subsequent products to also react with the huge excess of reagent B.
=== Laboratory preparation === Rarely is there any interest in the synthesis of alkanes, since they are usually commercially available and less valued than virtually any precursor. The best-known method is hydrogenation of alkenes. Many C−X bonds can be converted to C−H bonds using lithium aluminium hydride, Clemmenson reduction, and other specialized routes. Hydrolysis of alkyl Grignard reagents and alkyl organolithium reagents gives alkanes.
In the same month, France, the United States and Russia scheduled high-level, multi-country diplomatic visits in Africa. Reporting on these trips, Associated Press quoted William Gumede of Democracy Works saying "It’s like a new Cold War is playing out in Africa, where the rival sides are trying to gain influence" used the term "new Cold War"; AP commented "some say is the most intense competition for influence [in Africa] since the Cold War". An editorial by Christian Breuer said "It is conceivable that we see the rebirth of a new era of conflict, the end of the late 20th century unipolar international security architecture under the hegemony of the United States, the end of globalisation and the beginning of a new cold war between the West and the East." In August 2022, an analysis by journalist Anshel Pfeffer in Haaretz used the term to refer to the US's "open confrontation with Russia and China", concluding that "in the new Cold War, [Israel] cannot allow itself to be neutral". In the same month, Katrina vanden Heuvel cautioned against what she perceived as a "reflexive bipartisan embrace of a new Cold War" against Russia and China among US politicians. In September 2022, Greek civil engineer and politician Anna Diamantopoulou stated that, despite unity of NATO members, "the West has lost much of its normative power", citing her "meetings with politicians from Africa, Latin America, and the Middle East". She further stated that the West will risk losing "a new cold war" unless it overcomes challenges that would give Russia and China a greater world advantage.
== Name == The name açaí is a language variation of the Tupian word ïwasa’i, meaning “fruit that cries or expels water.” In the binomial nomenclature, the genus Euterpe refers to the tree’s growth habit. Its specific epithet oleracea means "vegetable" in Latin, referring to the fruit as edible.
== Prevention == There is ongoing research for methods to prevent type 1 diabetes. The development of diabetes symptoms can be delayed in some people who are at high risk of developing the disease. In 2022, the FDA approved an intravenous injection of teplizumab to delay the progression of type 1 diabetes in those older than eight who have already developed diabetes-related autoantibodies and problems with blood sugar control. In that population, the anti-CD3 monoclonal antibody teplizumab can delay the development of type 1 diabetes symptoms by around two years. In addition to anti-CD3 antibodies, several other immunosuppressive agents have been trialled to prevent beta cell destruction. Large trials of cyclosporine treatment suggested that cyclosporine could improve insulin secretion in those recently diagnosed with type 1 diabetes; however, people who stopped taking cyclosporine rapidly stopped making insulin, and cyclosporine's kidney toxicity and increased risk of cancer prevented people from using it long-term. Several other immunosuppressive agents – prednisone, azathioprine, anti-thymocyte globulin, mycophenolate, and antibodies against CD20 and IL2 receptor α – have been the subject of research. None has provided lasting protection from the development of type 1 diabetes. There have also been clinical trials attempting to induce immune tolerance by vaccination with insulin, GAD65, and various short peptides targeted by immune cells during type 1 diabetes; none have yet delayed or prevented development of disease.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.